Continuum Advisory’s INmune Bio INMB Stock Holding History

Continuum Advisory’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,000	Closed	-$7.81K	–	979
2025 Q1	$7.81K	Hold	1,000	–	–	﹤0.01%	1037
2024 Q4	$4.67K	Hold	1,000	–	–	﹤0.01%	1155
2024 Q3	$5.44K	Hold	1,000	–	–	﹤0.01%	1132
2024 Q2	$8.82K	Hold	1,000	–	–	﹤0.01%	982
2024 Q1	$10.8K	Buy	+1,000	New	+$12.1K	﹤0.01%	926

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Continuum Advisory's INMB Position: Q2 2025 in Review

Continuum Advisory sold out of INmune Bio (INMB) in Q2 2025, closing a stake of 1,000 shares — an estimated $7.81K sold.

Continuum Advisory first reported a position in INMB in Q1 2024 and held it in 5 quarters. The position peaked at $10.8K in Q1 2024. 79 funds tracked by Wall St. Rank hold INMB as of Q2 2025.

Continuum Advisory reported no remaining INmune Bio position as of Q2 2025 after selling out during the quarter.
Continuum Advisory sold 1,000 INmune Bio shares in Q2 2025, an estimated $7.81K.
Continuum Advisory first reported a position in INmune Bio in Q1 2024 and held it in 5 quarters.
Continuum Advisory's INmune Bio position peaked at $10.8K in Q1 2024.
79 funds tracked by Wall St. Rank held INmune Bio as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.